ArticleThe Lancet regional health. Western Pacific2025

A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients.

Yuji Hiromatsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.